vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
TRANSACT TECHNOLOGIES INC is the larger business by last-quarter revenue ($11.5M vs $8.1M, roughly 1.4× Arcellx, Inc.). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs -79.3%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-63.9M). Over the past eight quarters, TRANSACT TECHNOLOGIES INC's revenue compounded faster (3.5% CAGR vs -24.6%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
ACLX vs TACT — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $11.5M |
| Net Profit | $-62.3M | — |
| Gross Margin | — | 47.6% |
| Operating Margin | -847.6% | -10.1% |
| Net Margin | -766.0% | — |
| Revenue YoY | -79.3% | 11.9% |
| Net Profit YoY | -765.1% | — |
| EPS (diluted) | $-1.13 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $11.5M | ||
| Q3 25 | — | $13.2M | ||
| Q2 25 | — | $13.8M | ||
| Q1 25 | $8.1M | $13.1M | ||
| Q4 24 | $15.3M | $10.2M | ||
| Q3 24 | $26.0M | $10.9M | ||
| Q2 24 | $27.4M | $11.6M | ||
| Q1 24 | $39.3M | $10.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $15.0K | ||
| Q2 25 | — | $-143.0K | ||
| Q1 25 | $-62.3M | $19.0K | ||
| Q4 24 | $-47.1M | — | ||
| Q3 24 | $-25.9M | $-551.0K | ||
| Q2 24 | $-27.2M | $-319.0K | ||
| Q1 24 | $-7.2M | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | — | -10.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | -1.9% | ||
| Q1 25 | -847.6% | -0.1% | ||
| Q4 24 | -348.2% | -10.3% | ||
| Q3 24 | -129.1% | -7.7% | ||
| Q2 24 | -127.8% | -3.8% | ||
| Q1 24 | -40.3% | -12.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | -1.0% | ||
| Q1 25 | -766.0% | 0.1% | ||
| Q4 24 | -308.4% | — | ||
| Q3 24 | -99.4% | -5.1% | ||
| Q2 24 | -99.3% | -2.8% | ||
| Q1 24 | -18.3% | -9.7% |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | $-1.13 | $0.00 | ||
| Q4 24 | $-0.87 | $-0.80 | ||
| Q3 24 | $-0.48 | $-0.06 | ||
| Q2 24 | $-0.51 | $-0.03 | ||
| Q1 24 | $-0.14 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $543.3M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $416.9M | $31.1M |
| Total Assets | $648.1M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $20.4M | ||
| Q3 25 | — | $20.0M | ||
| Q2 25 | — | $17.7M | ||
| Q1 25 | $543.3M | $14.2M | ||
| Q4 24 | $587.4M | $14.4M | ||
| Q3 24 | $574.3M | $11.3M | ||
| Q2 24 | $516.7M | $11.1M | ||
| Q1 24 | $573.9M | $10.6M |
| Q4 25 | — | $31.1M | ||
| Q3 25 | — | $31.8M | ||
| Q2 25 | — | $31.3M | ||
| Q1 25 | $416.9M | $30.9M | ||
| Q4 24 | $454.8M | $30.6M | ||
| Q3 24 | $483.0M | $38.4M | ||
| Q2 24 | $487.2M | $38.5M | ||
| Q1 24 | $496.6M | $38.6M |
| Q4 25 | — | $44.8M | ||
| Q3 25 | — | $45.0M | ||
| Q2 25 | — | $44.5M | ||
| Q1 25 | $648.1M | $44.2M | ||
| Q4 24 | $711.3M | $44.0M | ||
| Q3 24 | $764.9M | $50.5M | ||
| Q2 24 | $734.3M | $50.4M | ||
| Q1 24 | $779.7M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.1M | $609.0K |
| Free Cash FlowOCF − Capex | $-63.9M | $589.0K |
| FCF MarginFCF / Revenue | -786.4% | 5.1% |
| Capex IntensityCapex / Revenue | 9.6% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-122.5M | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $609.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | $-63.1M | $-161.0K | ||
| Q4 24 | $-46.0M | $2.4M | ||
| Q3 24 | $30.7M | $327.0K | ||
| Q2 24 | $-36.2M | $636.0K | ||
| Q1 24 | $-31.9M | $-1.5M |
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | $-63.9M | $-171.0K | ||
| Q4 24 | $-47.5M | $2.4M | ||
| Q3 24 | $28.4M | $259.0K | ||
| Q2 24 | $-39.5M | $499.0K | ||
| Q1 24 | $-38.3M | $-1.6M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 25.9% | ||
| Q1 25 | -786.4% | -1.3% | ||
| Q4 24 | -311.3% | 23.2% | ||
| Q3 24 | 109.2% | 2.4% | ||
| Q2 24 | -144.1% | 4.3% | ||
| Q1 24 | -97.7% | -14.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | 9.6% | 0.1% | ||
| Q4 24 | 9.8% | 0.1% | ||
| Q3 24 | 8.8% | 0.6% | ||
| Q2 24 | 11.7% | 1.2% | ||
| Q1 24 | 16.4% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
